198 related articles for article (PubMed ID: 16276484)
1. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients.
Malacarne F; Benicchi T; Notarangelo LD; Mori L; Parolini S; Caimi L; Hershfield M; Notarangelo LD; Imberti L
Eur J Immunol; 2005 Nov; 35(11):3376-86. PubMed ID: 16276484
[TBL] [Abstract][Full Text] [Related]
2. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
[TBL] [Abstract][Full Text] [Related]
3. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.
Apasov SG; Blackburn MR; Kellems RE; Smith PT; Sitkovsky MV
J Clin Invest; 2001 Jul; 108(1):131-41. PubMed ID: 11435465
[TBL] [Abstract][Full Text] [Related]
4. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.
Serana F; Sottini A; Chiarini M; Zanotti C; Ghidini C; Lanfranchi A; Notarangelo LD; Caimi L; Imberti L
J Immunol; 2010 Dec; 185(12):7713-22. PubMed ID: 21057082
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
Hershfield MS; Chaffee S; Sorensen RU
Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
Hershfield MS
Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
[No Abstract] [Full Text] [Related]
8. Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.
Liu P; Santisteban I; Burroughs LM; Ochs HD; Torgerson TR; Hershfield MS; Rawlings DJ; Scharenberg AM
Clin Immunol; 2009 Feb; 130(2):162-74. PubMed ID: 18952502
[TBL] [Abstract][Full Text] [Related]
9. polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency.
Lainka E; Hershfield MS; Santisteban I; Bali P; Seibt A; Neubert J; Friedrich W; Niehues T
Clin Diagn Lab Immunol; 2005 Jul; 12(7):861-6. PubMed ID: 16002636
[TBL] [Abstract][Full Text] [Related]
10. Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.
Moretti FA; Giardino G; Attenborough TCH; Gkazi AS; Margetts BK; la Marca G; Fairbanks L; Crompton T; Gaspar HB
Sci Rep; 2021 Dec; 11(1):23221. PubMed ID: 34853379
[TBL] [Abstract][Full Text] [Related]
11. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
[TBL] [Abstract][Full Text] [Related]
12. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
13. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
Blaese RM; Culver KW; Miller AD; Carter CS; Fleisher T; Clerici M; Shearer G; Chang L; Chiang Y; Tolstoshev P; Greenblatt JJ; Rosenberg SA; Klein H; Berger M; Mullen CA; Ramsey WJ; Muul L; Morgan RA; Anderson WF
Science; 1995 Oct; 270(5235):475-80. PubMed ID: 7570001
[TBL] [Abstract][Full Text] [Related]
14. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation.
Sarzotti M; Patel DD; Li X; Ozaki DA; Cao S; Langdon S; Parrott RE; Coyne K; Buckley RH
J Immunol; 2003 Mar; 170(5):2711-8. PubMed ID: 12594301
[TBL] [Abstract][Full Text] [Related]
15. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
[No Abstract] [Full Text] [Related]
16. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
Bory C; Boulieu R; Souillet G; Hershfield MS
Therapie; 1991; 46(4):323-6. PubMed ID: 1948809
[TBL] [Abstract][Full Text] [Related]
17. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
18. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
19. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities.
Blackburn MR; Aldrich M; Volmer JB; Chen W; Zhong H; Kelly S; Hershfield MS; Datta SK; Kellems RE
J Biol Chem; 2000 Oct; 275(41):32114-21. PubMed ID: 10908569
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
Girault D; Le Deist F; Debré M; Pérignon JL; Herbelin C; Griscelli C; Sciudery D; Hershfield M; Fischer A
Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
